Lakefront Biotherapeutics LKFT
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 61st percentile, 5-year average 15.3x
#119 of 2994 stocks by PE (1 = cheapest)
Below its usual level · 27th percentile, 5-year average 0.9x
#809 of 5335 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 16th percentile, 5-year average 4.8x
#2677 of 5159 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 0.63 | – | 0.91 | 27% (cheaper than usual) | #809 of 5335 (1 = cheapest) |
| PE | 2.55 | -21.92 | 15.34 | 61% (pricier than usual) | #119 of 2994 (1 = cheapest) |
| PS | 2.19 | 62.69 | 4.83 | 16% (cheaper than usual) | #2677 of 5159 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on LKFT.
Sign in to join the discussion.